Tazuma S, Hatsushika S, Aihara N, Sagawa H, Yamashita G, Sasaki M, Sasaki H, Mizuno S, Tao S, Kajiyama G
First Department of Internal Medicine, Hiroshima University School of Medicine, Japan.
Digestion. 1992;51(3):179-84. doi: 10.1159/000200894.
The effects of pravastatin on cholesterol gallstone formation were determined in prairie dogs. We fed 10 prairie dogs 1% cholesterol with or without 0.05% (w/w) pravastatin (n = 5, each) for 4 weeks. In addition, another 5 prairie dogs were fed a standard rodent chow as a control. Only the animals fed 1% cholesterol without pravastatin treatment formed cholesterol gallstones. Gallbladder bile from cholesterol-fed animals contained cholesterol monohydrate crystals, whereas those treated with pravastatin contained no crystal. Furthermore, marked increases in tissue cholesterol levels (serum, liver and bile), and in biliary mucous glycoprotein levels were evident in cholesterol-fed animals, whereas pravastatin treatment normalized these levels. These findings raise the possibility that such inhibitors might have a future role to play in the prevention of cholesterol gallstone formation and/or recurrence.
在草原犬鼠中测定了普伐他汀对胆固醇性胆结石形成的影响。我们给10只草原犬鼠喂食含1%胆固醇的食物,其中5只添加0.05%(w/w)普伐他汀,另5只不添加(每组n = 5),持续4周。此外,另外5只草原犬鼠喂食标准啮齿动物饲料作为对照。只有未接受普伐他汀治疗、喂食1%胆固醇的动物形成了胆固醇性胆结石。喂食胆固醇的动物的胆囊胆汁中含有一水合胆固醇晶体,而接受普伐他汀治疗的动物的胆囊胆汁中没有晶体。此外,喂食胆固醇的动物的组织胆固醇水平(血清、肝脏和胆汁)以及胆汁粘蛋白糖蛋白水平显著升高,而普伐他汀治疗使这些水平恢复正常。这些发现增加了这样一种可能性,即此类抑制剂可能在预防胆固醇性胆结石形成和/或复发方面发挥未来作用。